Two Biologics Work Equally Well for Active Crohn’s Disease

For adults with moderate to severe Crohn’s disease who have never been on a biologic agent, treatment with monotherapy with adalimumab or ustekinumab appear to be equally effective, according to results of the head-to-head SEAVUE trial.
Reuters Health Information

Leave a Reply

Your email address will not be published. Required fields are marked *